These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36190203)

  • 1. Post COVID-19 vaccination: AusVaxSafety survey participation and adverse events - a community-based regional Queensland study.
    Hamilton E; Oversby S; Kitchener S; Ratsch A
    Aust N Z J Public Health; 2022 Dec; 46(6):738-744. PubMed ID: 36190203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.
    Deng L; Glover C; Dymock M; Pillsbury A; Marsh JA; Quinn HE; Leeb A; Cashman P; Snelling TL; Wood N; Macartney K
    Med J Aust; 2022 Aug; 217(4):195-202. PubMed ID: 35781813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing adverse events following COVID-19 vaccination.
    Villanueva P; McDonald E; Croda J; Croda MG; Dalcolmo M; Dos Santos G; Jardim B; Lacerda M; Lynn DJ; Marshall H; Oliveira RD; Rocha J; Sawka A; Val F; Pittet LF; Messina NL; Curtis N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2323853. PubMed ID: 38445666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom.
    Otero-Losada M; Petrovsky N; Alami A; Crispo JA; Mattison D; Capani F; Goetz C; Krewski D; Perez-Lloret S
    Expert Opin Drug Saf; 2023 Apr; 22(4):343-349. PubMed ID: 36043937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
    Lopez Bernal J; Andrews N; Gower C; Robertson C; Stowe J; Tessier E; Simmons R; Cottrell S; Roberts R; O'Doherty M; Brown K; Cameron C; Stockton D; McMenamin J; Ramsay M
    BMJ; 2021 May; 373():n1088. PubMed ID: 33985964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
    Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
    Front Immunol; 2022; 13():956825. PubMed ID: 36177033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
    Osowicki J; Morgan HJ; Harris A; Clothier HJ; Buttery JP; Kiers L; Crawford NW;
    Vaccine; 2022 Dec; 40(52):7579-7585. PubMed ID: 36357291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance of adverse events following immunisation in Australia, COVID-19 vaccines, 2021.
    Glover C; Deng L; Larter C; Brogan C; Richardson O; Huang YA; Kay E; Macartney K; Wood N
    Commun Dis Intell (2018); 2024 Jun; 48():. PubMed ID: 38926650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety.
    Glover C; Crawford N; Leeb A; Wood N; Macartney K
    Vaccine; 2020 Jun; 38(31):4892-4900. PubMed ID: 32499067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active Safety Surveillance of Four Types of COVID-19 Vaccines: A National Study from Jordan.
    Abdel-Qader DH; Abdel-Qader H; Silverthorne J; Kongkaew C; Al Meslamani AZ; Hayajneh W; Ata OMA; Shnaigat W; AbuRuz S; Al Nsour M; Alhariri A; Shnewer K; Da'ssan M; Obeidat NM; Nusair KE; Jalamdeh MS; Hawari F; Khader K; Hakim T; Hammad FA; Al Qudah M; Asad M
    Clin Drug Investig; 2022 Oct; 42(10):813-827. PubMed ID: 35999428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.
    Tran VN; Nguyen HA; Le TTA; Truong TT; Nguyen PT; Nguyen TTH
    Vaccine; 2021 Oct; 39(44):6485-6491. PubMed ID: 34607748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events following immunisation of COVID-19 vaccine among health care workers in the first phase of vaccination.
    Rahmat H; Leelavathi M; Wan Ismail WF
    Med J Malaysia; 2022 Nov; 77(6):637-642. PubMed ID: 36448378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France.
    Botton J; Jabagi MJ; Bertrand M; Baricault B; Drouin J; Le Vu S; Weill A; Farrington P; Zureik M; Dray-Spira R
    Ann Intern Med; 2022 Sep; 175(9):1250-1257. PubMed ID: 35994748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations.
    Salter SM; Li D; Trentino K; Nissen L; Lee K; Orlemann K; Peters I; Murray K; Leeb A; Deng L
    Vaccines (Basel); 2022 Nov; 10(12):. PubMed ID: 36560426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021.
    Fortunato F; Prato R; Iannelli G; Ascatigno L; Loconsole D; Lopalco PL; Martinelli D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2209919. PubMed ID: 37226552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events following immunization of COVID-19 vaccine among children aged 6-11 years.
    Puspitarani F; Sitaresmi MN; Ahmad RA
    Front Public Health; 2022; 10():999354. PubMed ID: 36388348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19.
    Wei J; Zhang W; Doherty M; Wallace ZS; Sparks JA; Lu N; Li X; Zeng C; Lei G; Zhang Y
    BMC Med; 2023 Feb; 21(1):78. PubMed ID: 36855108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study.
    Mascolo A; di Mauro G; Fraenza F; Gaio M; Zinzi A; Pentella C; Rossi F; Capuano A; Sportiello L
    Front Immunol; 2022; 13():965171. PubMed ID: 36263025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
    Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.